Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape.
Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
